Lilly France

What Lilly France does

Lilly France is the French operating subsidiary of Eli Lilly and Company (NYSE: LLY), the global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The French entity was established in 1962 and currently employs between 1,001 and 5,000 people. It commercializes a portfolio of prescription medications across seven core therapeutic areas: oncology, dermatology, arthritis, sleep apnea, diabetes, obesity, and Alzheimer's disease. Distribution is conducted through regulated French pharmaceutical supply chains — pharmacies, hospitals, and healthcare institutions — under pricing terms set by national reimbursement authorities and not publicly disclosed.

The company's core technology centers on pharmaceutical research, drug development, and manufacturing, with explicit R&D investment in genetic medicine aimed at producing personalized treatments derived from individual genetic code. Lilly France leverages the parent company's broader pipeline and manufacturing infrastructure, drawing on over 100 patented medicines, 150 years of pharmaceutical manufacturing experience, and two Nobel Prizes in medicine awarded to Lilly researchers. Manufacturing and quality assurance are positioned as core operational competencies, with continuous production to high regulatory standards emphasized on the French website.

The revenue model is based on prescription pharmaceutical product sales distributed via licensed French healthcare channels. The go-to-market motion is healthcare-provider oriented, supported by disease-awareness content marketing through pathology-specific resource pages targeting both prescribers and patients/caregivers. Primary customer segments are physicians and healthcare professionals who prescribe Lilly medications, and patients and caregivers seeking disease education and treatment information across chronic and complex conditions. The commercial strategy combines traditional pharmaceutical sales with patient-engagement content across all seven therapeutic verticals.

Name

Lilly France

Legal name

Lilly France

Website

https://lilly.fr

Company type

Private

Founded year

1962

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Lilly France is the French operating subsidiary of Eli Lilly and Company, marketing prescription medications across seven therapeutic areas including oncology, diabetes, obesity, and Alzheimer's to French healthcare providers, hospitals, pharmacies, and patients.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Prescription pharmaceuticals
• Oncology medications
• Diabetes treatments
• Pharmaceutical manufacturing
• Genetic medicine research

Headquarters

HQ city

Indianapolis

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from the sale of patented prescription medications across therapeutic areas including oncology, dermatology, immunology, endocrinology, and neurology. The company manufactures and distributes medications through pharmaceutical supply chains.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Lilly France develops, manufactures, and distributes patented prescription medications across seven therapeutic areas: oncology (cancer), dermatology, arthritis, sleep apnea, diabetes, obesity, and Alzheimer's disease. Operations include continuous high-quality manufacturing under pharmaceutical regulatory standards and proprietary research into genetic-based personalized medicine. Distribution occurs through licensed pharmacies, hospitals, and healthcare institutions throughout France.

Product overview

Lilly France operates as a pharmaceutical company offering a portfolio of prescription medications across seven core therapeutic areas: oncology (cancer), dermatology, arthritis, sleep apnea, diabetes, obesity, and Alzheimer's disease. The company leverages 150 years of manufacturing experience and over 100 patented medicines to deliver treatments that meet high quality standards. Lilly France's product portfolio consists of distinct branded medications organized by pathology, with each therapeutic area representing a specialized product line targeting specific disease conditions. The company also invests in genetic medicine research for future personalized treatments based on individual genetic code.

Differentiator

Problem solved

Functional benefit

Products and services

• Médicaments anticancéreux (Cancer treatments) Pharmaceutical treatments developed for cancer therapy across various cancer types, distributed through licensed pharmacies and healthcare institutions in France.
• Médicaments dermatologiques (Dermatology treatments) Pharmaceutical treatments for dermatological conditions and skin diseases, dispensed through the French pharmaceutical distribution network.
• Médicaments anti-arthrite (Arthritis treatments) Pharmaceutical treatments for arthritis and joint-related conditions, prescribed by healthcare providers and distributed via licensed channels in France.
• Traitements de l'apnée du sommeil (Sleep apnea treatments) Pharmaceutical treatments for sleep apnea and related sleep disorders, distributed through French pharmacies and healthcare institutions.
• Médicaments antidiabétiques (Diabetes treatments) Pharmaceutical treatments for diabetes management and blood sugar control, prescribed by healthcare providers and dispensed through the French pharmaceutical supply chain.
• Traitements de l'obésité (Obesity treatments) Pharmaceutical treatments for obesity and weight management, distributed through licensed pharmacies and healthcare institutions in France.
• Traitements de la maladie d'Alzheimer (Alzheimer's disease treatments) Pharmaceutical treatments for Alzheimer's disease and neurodegenerative conditions, prescribed by specialist physicians and distributed via hospitals and pharmacies in France.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Pfizer: Pfizer is a broad incumbent pharmaceutical company with operations in France and overlapping therapeutic areas including oncology, dermatology, and chronic disease management.
• Novo Nordisk: Novo Nordisk is the global leader in diabetes and obesity care with its GLP-1 franchise (Ozempic, Wegovy), directly competing with Lilly France in two of its core therapeutic areas (diabetes and obesity).
• Roche: Roche is a major pharmaceutical company with a strong oncology and neurology presence in France, directly overlapping with Lilly France's oncology and Alzheimer's therapeutic areas.
• GSK: GSK has a significant French pharmaceutical presence and overlapping franchises in dermatology, respiratory, and immunology, comparable to several Lilly France therapeutic areas.
• Sanofi: Sanofi is a French-headquartered global pharmaceutical company with overlapping therapeutic areas including diabetes, oncology, dermatology, and rare diseases, and is a direct competitor to Lilly France on French soil.
• Boehringer Ingelheim: Boehringer Ingelheim is a major privately-held pharmaceutical company with French operations and strong diabetes and respiratory franchises that overlap with Lilly France's diabetes and sleep apnea areas.
• AstraZeneca: AstraZeneca is a major pharmaceutical company with significant French operations and overlapping focus in oncology, diabetes-adjacent cardiometabolic care, and respiratory/sleep disorders.
• Merck & Co. Merck (MSD in Europe) is a major pharmaceutical incumbent with oncology, dermatology, and neurology franchises that compete with Lilly France's portfolio in the French market.
• Novartis: Novartis operates significant pharmaceutical franchises in France across oncology, dermatology, and immunology, overlapping with multiple Lilly France therapeutic areas.
• Bayer Pharmaceuticals: Bayer's pharmaceutical division operates in France with therapeutic franchises in cardiology, oncology, and women's health, providing overlap with several of Lilly France's chronic disease areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks3 records

Key highlights6 records

Customer concentration

• Xx.com/LillyPadFR

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lilly France